Ben Boursi1, Ronac Mamtani2, Kevin Haynes2, Yu-Xiao Yang2. 1. Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania, USAThe Integrated Cancer Prevention CenterTel-Aviv Sourasky Medical Center, Tel-Aviv, IsraelTel-Aviv UniversityTel-Aviv, Israel Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania, USAThe Integrated Cancer Prevention CenterTel-Aviv Sourasky Medical Center, Tel-Aviv, IsraelTel-Aviv UniversityTel-Aviv, Israel Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania, USAThe Integrated Cancer Prevention CenterTel-Aviv Sourasky Medical Center, Tel-Aviv, IsraelTel-Aviv UniversityTel-Aviv, Israel. 2. Perelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania, USAThe Integrated Cancer Prevention CenterTel-Aviv Sourasky Medical Center, Tel-Aviv, IsraelTel-Aviv UniversityTel-Aviv, Israel.
Abstract
OBJECTIVE: Gut microbiota influence metabolic pathways related to the pathogenesis of obesity, insulin-resistance and diabetes. Antibiotic therapy can alter the microbiota, and is commonly used in western countries. We sought to evaluate whether past antibiotic exposure increases diabetes risk. RESEARCH DESIGN AND METHODS: We conducted a nested case-control study using a large population-based database from the UK. The cases were defined as those with incident diagnosis of diabetes. For every case, four eligible controls matched on age, sex, practice-site, and duration of follow-up before index-date were selected using incidence-density sampling. Exposure of interest was antibiotic therapy >1 year before index-date. Odds ratios (ORs) and 95% CIs were estimated using conditional logistic regression. The risk was adjusted for BMI, smoking, last glucose level, and number of infections before index-date, as well as past medical history of coronary artery disease and hyperlipidaemia. RESULTS: The study included 208 002 diabetic cases and 815 576 matched controls. Exposure to a single antibiotic prescription was not associated with higher adjusted diabetes risk. Treatment with two to five antibiotic courses was associated with increase in diabetic risk for penicillin, cephalosporins, macrolides and quinolones with adjusted OR ranging from 1.08 (95% CI 1.05-1.11) for penicillin to 1.15 (95% CI 1.08-1.23) for quinolones. The risk increased with the number of antibiotic courses and reached 1.37 (95% CI 1.19-1.58) for more than 5 courses of quinolones. There was no association between exposure to anti-virals and anti-fungals and diabetes risk. CONCLUSIONS: Exposure to certain antibiotic groups increases diabetes risk.
OBJECTIVE: Gut microbiota influence metabolic pathways related to the pathogenesis of obesity, insulin-resistance and diabetes. Antibiotic therapy can alter the microbiota, and is commonly used in western countries. We sought to evaluate whether past antibiotic exposure increases diabetes risk. RESEARCH DESIGN AND METHODS: We conducted a nested case-control study using a large population-based database from the UK. The cases were defined as those with incident diagnosis of diabetes. For every case, four eligible controls matched on age, sex, practice-site, and duration of follow-up before index-date were selected using incidence-density sampling. Exposure of interest was antibiotic therapy >1 year before index-date. Odds ratios (ORs) and 95% CIs were estimated using conditional logistic regression. The risk was adjusted for BMI, smoking, last glucose level, and number of infections before index-date, as well as past medical history of coronary artery disease and hyperlipidaemia. RESULTS: The study included 208 002 diabetic cases and 815 576 matched controls. Exposure to a single antibiotic prescription was not associated with higher adjusted diabetes risk. Treatment with two to five antibiotic courses was associated with increase in diabetic risk for penicillin, cephalosporins, macrolides and quinolones with adjusted OR ranging from 1.08 (95% CI 1.05-1.11) for penicillin to 1.15 (95% CI 1.08-1.23) for quinolones. The risk increased with the number of antibiotic courses and reached 1.37 (95% CI 1.19-1.58) for more than 5 courses of quinolones. There was no association between exposure to anti-virals and anti-fungals and diabetes risk. CONCLUSIONS: Exposure to certain antibiotic groups increases diabetes risk.
Authors: Carlotta De Filippo; Duccio Cavalieri; Monica Di Paola; Matteo Ramazzotti; Jean Baptiste Poullet; Sebastien Massart; Silvia Collini; Giuseppe Pieraccini; Paolo Lionetti Journal: Proc Natl Acad Sci U S A Date: 2010-08-02 Impact factor: 11.205
Authors: Matam Vijay-Kumar; Jesse D Aitken; Frederic A Carvalho; Tyler C Cullender; Simon Mwangi; Shanthi Srinivasan; Shanthi V Sitaraman; Rob Knight; Ruth E Ley; Andrew T Gewirtz Journal: Science Date: 2010-03-04 Impact factor: 47.728
Authors: Fredrik H Karlsson; Valentina Tremaroli; Intawat Nookaew; Göran Bergström; Carl Johan Behre; Björn Fagerberg; Jens Nielsen; Fredrik Bäckhed Journal: Nature Date: 2013-05-29 Impact factor: 49.962
Authors: Patrice D Cani; Jacques Amar; Miguel Angel Iglesias; Marjorie Poggi; Claude Knauf; Delphine Bastelica; Audrey M Neyrinck; Francesca Fava; Kieran M Tuohy; Chantal Chabo; Aurélie Waget; Evelyne Delmée; Béatrice Cousin; Thierry Sulpice; Bernard Chamontin; Jean Ferrières; Jean-François Tanti; Glenn R Gibson; Louis Casteilla; Nathalie M Delzenne; Marie Christine Alessi; Rémy Burcelin Journal: Diabetes Date: 2007-04-24 Impact factor: 9.461
Authors: Husen Zhang; John K DiBaise; Andrea Zuccolo; Dave Kudrna; Michele Braidotti; Yeisoo Yu; Prathap Parameswaran; Michael D Crowell; Rod Wing; Bruce E Rittmann; Rosa Krajmalnik-Brown Journal: Proc Natl Acad Sci U S A Date: 2009-01-21 Impact factor: 11.205
Authors: Mora Murri; Isabel Leiva; Juan Miguel Gomez-Zumaquero; Francisco J Tinahones; Fernando Cardona; Federico Soriguer; María Isabel Queipo-Ortuño Journal: BMC Med Date: 2013-02-21 Impact factor: 8.775
Authors: Peter J Turnbaugh; Micah Hamady; Tanya Yatsunenko; Brandi L Cantarel; Alexis Duncan; Ruth E Ley; Mitchell L Sogin; William J Jones; Bruce A Roe; Jason P Affourtit; Michael Egholm; Bernard Henrissat; Andrew C Heath; Rob Knight; Jeffrey I Gordon Journal: Nature Date: 2008-11-30 Impact factor: 49.962
Authors: Ben Boursi; Brian Finkelman; Bruce J Giantonio; Kevin Haynes; Anil K Rustgi; Andrew D Rhim; Ronac Mamtani; Yu-Xiao Yang Journal: Gastroenterology Date: 2016-12-05 Impact factor: 22.682
Authors: Jiangwei Yao; Robert A Carter; Grégoire Vuagniaux; Maryse Barbier; Jason W Rosch; Charles O Rock Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191